Nebojsa Janjic
Presidente en Crestone, Inc. .
Perfil
Nebojsa Janjic was the founder of Replidyne, Inc. which was founded in 2000 where he held the position of Secretary & Chief Scientific Officer until 2008.
He is currently the Chairman at Crestone, Inc. and the Chief Science Officer at SomaLogic Operating Co., Inc. since 2009.
Dr. Janjic was a Senior Director-Drug Discovery at NeXstar Pharmaceuticals, Inc. from 1992 to 1999 and also held the position of Chief Science Officer at SomaLogic, Inc. Dr. Janjic received his undergraduate and doctorate degrees from the University of Washington.
Cargos activos de Nebojsa Janjic
Empresas | Cargo | Inicio |
---|---|---|
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Director Técnico/Científico/I+D | 01/01/2009 |
Crestone, Inc. | Presidente | - |
Antiguos cargos conocidos de Nebojsa Janjic.
Empresas | Cargo | Fin |
---|---|---|
STANDARD BIOTOOLS INC. | Director Técnico/Científico/I+D | 05/01/2024 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Fundador | 08/12/2008 |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Corporate Officer/Principal | 01/01/1999 |
Formación de Nebojsa Janjic.
University of Washington | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
STANDARD BIOTOOLS INC. | Commercial Services |
Empresas privadas | 4 |
---|---|
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Health Technology |
Crestone, Inc. |
- Bolsa de valores
- Insiders
- Nebojsa Janjic